home | our doctors | our staff | about us | contact us

Dr. Victor H. Gonzalez

Dr. Victor H. Gonzalez is the founder of Valley Retina Institute, P.A., a state of the
art medical and surgical vitreo-retinal practice serving the Rio Grande Valley.


















 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Having trouble reading the small print:

+ Larger Font | + Smaller Font 

 

Personal Information


Name: Victor Hugo Gonzalez, M.D.
Business Address: Valley Retina Institute, P.A.
1309 E. Ridge Road, Suite 1
McAllen, TX 78503
Business Phone: (956) 631-8875

Arriba Top

Education and Training

 
Vitreoretinal Fellowship: Massachusetts Eye and Ear Infirmary
Harvard Medical School
Boston, Massachusetts
1992-1994
Residency: Doheny Eye Institute at Los Angeles County Hospital
Los Angeles, California
1989-1992
Internship: Cedars-Sinai Medical Center
Los Angeles, California
1988-1989
Medical School: Harvard Medical School
1988
University: Princeton University
B.A., Chemistry
1984

Arriba Top

Professional Organizations

 
American Academy of Ophthalmology Research to Prevent Blindness
American Diabetes Association Schepens International Society
American Medical Association Texas Medical Association
Association for Research in Vision and Ophthalmology Texas Ophthalmologic Association
California Association of Ophthalmology The Retina Society
Pan American Ophthalmological Society The Vitreous Society
Pinnacle Society, American Diabetes Association Association of Clinical Research Professionals

Arriba Top

Licenses and Certificates

 
California 1990
Massachusetts 1992
Texas 1994
National Board of Medical Examiners 1990
Diplomate of the American Board of Ophthalmology 1993

 

Abstracts

Gonzalez VH. Anatomical Considerations in Macular Hole Surgery [Abstract]. The Retina Society 33rd Scientific Session. Coral Gables, FL, 2000.
Mukai S, Regan CDJ, Gonzalez VH. Rabbit Model of Retinablastoma [Abstract] The Retina Society 26th Scientific Session. San Francisco, CA, 1993.
Hart L, Gonzalez VH, Gragoudas ES, Young LHY. Color Doppler Ultrasound in the Evaluation of Choroidal Melanoma Treatment Response to Photodynamic Therapy [Abstract]. ARVO, 1993.
Gonzalez VH, Theodossiadis P, Young LHY. Photodynamic Therapy of Pigmented Choroidal Melanomas [Abstract]. ARVO, 1993.
Gonzalez VH. The Effect of Aging on T-cell Activation via the CD2 Receptor [Abstract]. 37th Annual Conference of the National Council on the Aging. Chicago, IL, 1987.

 

Honors and Awards

 

NationsBank/Hispanic Magazine Adelante Awards

1998
Community Service Award, Princeton, New Jersey 1983
Princeton Medical Center Service Award 1984
Student-Faculty Class Representative, Harvard Medical School. 1985-1986
Geriatric Fellow-National Council on the Aging 1986-1987

 

Publications

Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Ruckert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS: The Da Vinci Study: Phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Opthalmology. 2011 Sep; 118(9):1819-26. doi: 1016/j.optha.2011.02.018. Epub 2011 May 5.
Fu YP, Hallman DM, Gonzalez VH, Klein BE, Klein R, Hayes MG, Cox NJ, Bell GI, Hanis CL: Identification of Diabetic Retinopathy Genes through a Genome-Wide Association Study among Mexican-Americans from Starr County, TX. J Ophtholmol. 2010; 2010. pii: 861291. doi: 10.1155/2010/861291. Epub 2010 Sep 2.
Gonzalez VH, Giuliari GP, Banda RM, Guel DA, Wingard M: Confluent laser photocoagulation for the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2010 Mar-Apr;47(2):81-5; quiz 86-7. doi: 10.3928/01913913-20100308-05. Epub 2010 Mar 22. Erratum in: J Pediatr Ophthalmol Strabismus. 2010 Sep-Oct;47(5):316. Guell, David A [corrected to Guel, David A].
Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group: A randomized trial comparing the efficacy of safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteriod for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009 Sep;127(9):1115-28. doi: 10.1001/archophthalmol.2009.233. Erratum in: Arch Ophthalmol. 2009 Dec;127(12):1655.
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group: A randomized trial comparing the efficacy of safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteriod for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep;127(9):1101-14. doi: 10.1001/archophthalmol.2009.234. Erratum in: Arch Ophthalmol. 2009 Dec;127(12):1648.
Aguilar D, Hallman DM, Piller LB, Klein BE, Klein R, Devereux RB, Arnett DK, Gonzalez VH, Hanis CL: Adverse association between diabetic retinopathy and cardiac structure and function. Am Heart J. 2009 Mar;157(3):563-8. doi: 10.1016/j.ahj.2008.10.019. Epub 2008 Dec 20.
Giuliari GP, Guel DA, Gonzalez VH: Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema. Curr Diabetes Rev. 2009 Feb; 5(1): 33-8. Review.
Gonzalez VH, Giuliari GP, Banda RM, Guel DA: Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol; 2009 Nov; 93 (11): 1474-8 PMID: 19692371
Ingrid U. Scott, MD, MPH (chair); Michael S. IP, MD; Paul C. VanVeldhuisen, PhD; Neal L. Oden, PhD; Barbara A. Blodi, MD; Marian Fisher, PhD; Clement K. Chan, MD; Victor H. Gonzalez, MD; Lawrence J. Singerman, MD; and Michael Tolentino, MD. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (Score) Study Report 6 Arch Ophthalmol; 2009;127(9):1115-1128
Gonzalez VH, Giuliari GP, Banda RM, Guel DA. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol. 2009 Nov; 939(11): 1474-8. Michael S. Ip, MD, Chair, Ingrid U. Scott, MD, MPH, Paul C. VanVeldhuisen, PhD, Neal L. Oden, PhD, Barbara A. Blodi, MD, Mirian Fisher, PhD, Lawrence J. Singerman, MD, Michael Tolentino, MD, Clement K. Chan, MD, and Victor H. Gonzalez, MD, A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion Arch Ophthalmol. 2009 September; 127 (9): 1101-1114.
Giuliari GP, Guel DA, Gonzalez VH. Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema, Current Diabetes Review 200, 5, 33-88.
Gonzalez VH, Banda R, Guel DA. Intravitreal Injection of Pegaptanib Sodium for Proliferative Diabetic Retinopathy: Interim Results of a Pilot Study. British Journal of Ophthalmology 2009; 93: 1474-1478 doi: 10.1136/bjo.2008.155663
Giuliari GP, Banda RM, Vann VR, Gonzalez VH, McMillin RB: Closed angle glaucoma after topiramate therepy for micraine in a patient with undiagnosed pseudotumor cerebri. Can J Ophthalmol. 2008 Jun;43(3):371. doi: 10.3129/i08-052. No abstract available.
Diabetic Retinopathy Clinical Research Network, Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C: Reproducibility of macular thickness and volume using Zeiss Optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007 Aug;114(8):1520-5. Epub 2007 Mar 13.
Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL: A genome-wide linkage scan for diabeic retinopathy susceptibility genes in Mexican Americans with type-2 diabetes from Starr County, Texas. Diabetes. 2007 Apr;56(4):1167-73. Epub 2007 Jan 24.
Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R, Hanis CL: Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005 May;28(5):1163-8.
Gonzalez VH. Laser and Pharmacologic Therapies in the Treatment of Diabetic Macular Edema. Retinal Physician. 2007
Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young LH. Photodynamic therapy of pigmented choroidal melanomas. Invest Ophthalmol Vis Sci. 1995 Apr;36(5):871-8.
Gonzalez VH, Ober R. Ocular Findings in Extracorporeal Membrane Oxygenator Survivors. Retina 1993; 13:202-7
Gritz CD, Kwito S, Trousdale M, Gonzalez VH, McDonnell P. Recurrence of Microbial keratitis Concomitant with Anti-Inflammatory treatment in animal model. Cornea, 1992; 11: 404-8
Gonzalez VH, McDonnell P. Computer-assisted corneal Topography in parents of patients with Keratoconus. Arch Ophthalmol, 1992; 110: 1412-14
Chofflon M, Gonzalez VH, Weiner HL, Hafler D. Inflammatory Cerebrospinal Fluid T-cells have activation requirements characteristic of CD4+CD45RA-T-cells. Euro J Immun, 1989; 19:1971-1975
Gonzalez VH. Purification, EPR and Fluorine NMR studies of 4-Hydroxphenylpyruvate Dioxygenase [Senior Thesis]. Princeton, New Jersey. Princeton University, 1984; 35 pp.
Gonzalez VH. Isolation of pyrocatechase [Junior Thesis]. Princeton, New Jersey. Princeton University, 1983. 15pp.
 


  Arriba Top

Lectures

Curso Internacional de Retina, Monterrey, NL-2007.
Retinal Physician, Roundtable Discussion, Diabetic and Ischemic Related Retinopathy-May 7, 2007.
ARVO, The Association for Research in Vision and Ophthalmology, Use of Pegaptanib Sodium (Macugen) for the Regression of Proliferative Diabetic Retinopathy, -May 2, 2006.
32 Congresso de Sociedade Brasileira de Retina e Vitreo, Macugen for Diabetic Retinopathy-April 14, 2007.
32 Congresso de Sociedade Brasileira de Retina e Vitreo, Anatomical Considerations Macular Hole Surgery-April 12, 2007.
Actualidades de Investigation en Oftalmologia, El Congreso Annual 2006 del Colegio de Oftamologia de Nuevo Léon-March 25, 2006.
Lucentis 2006 Retina Expert Meeting, Genetech-March 18, 2006 Vail Colorado.
World Ophthalmology Congress, Therapeutic Interventions for Macular Edema. February 18-22, 2006 Sao Paulo, Guarulh, Brazil.
Agujero Macular, Sociedad Ecuatoriana de Oftamologia Universidad Internacional del Ecuador, September 30, 2006.
Cirugia Actual de PVR, Sociedad Ecuatoriana de Oftalmologia Universisdad Internacional del Ecuador, September 30, 2006.
Manejo de Desprediimiento de Retina en Seudafaquia, Sociedad Ecuatoriana de Oftalmologia Universidad Internacional del Ecuador, September 30, 2006.
Tratamiento de DMRE Con Anti-VEGF, Sociedad Ecuatoriana de Oftalmologia Universidad Internacional del Ecuador, September 30, 2006.
Manejo de Nucleos luxados al Vitreo, Sociedad Ecuatoriana de Oftalmologia Universisdad Internacional del Ecuador September 30, 2006.
Curso de Retina, Sociedad Ecuatoriana de Oftalmologia Universidad Internacional del Ecuador, September 30, 2006.
Current Perspectives on Neovascular AMD for Referring Ophthalmologists. Midland, Texas- August 25, 2006.
Advisory Board Macugen, Macugeneracion. Mexico City, Mex- November 19, 2005.
Side by Side Presentation of Verteporfin and Pegaptanib Outcomes- September 24, 2005, Iguazu Falls, Argentina AMD Latin American Iguazu 2005 Panel Consultant Meeting.
Pegaptanib Trial Results-September 24, 2005, Iguazu Falls, Argentina AMD Latin American Iguazu 2005 Panel Consultant Meeting.
Rationale for combined Therepy: Verteporfin plus Triamcinolone Verteporfin plus Anit- Angiogenics- September 24, 2005, Iguazu Falls, Argentina AMD Latin American Iguaz 2005 Panel Consultant Meeting.
Familial Aggregation of Severity of Diabetic Retinopathy in Mexican Americans- September 17, 2005, San Diego, California The Retina Society- 38th Annual Scientific Meeting.
Panelist for Heath Summitt- September 13-14, 2005, Washington, D.C. Congressional Hispanic Caucus.
Anti-Angiogenics in the Manegement of Macular Edema- July 29, 2005, Nantucket, Massachusetts Nantucket Retina 19th Annual Meeting.
Combination Pharmacotherapy for Choroidal Neovascularization- June 18, 2005, Dallas, Texas New Treatment Approaches for Choroidal Neovascularization and Age-Related Macular Degeneration.
Practical Suggestion for Intravitreal Injections- June 18, 2005, Dallas, Texas New Treatment approaches for Choroidal Neovascularization and Age-Related Macular Degeneration.
International Symposium of Retinopathy of Prematurity. "Nuevas Indicaciones para Tratamiento de Retinopatia del Prematuro" -June 10-11, 2005. Universidad Autonoma de San Luis Potosi, Cuidad San Luis Potosi, SLP.
International Symposium of Retinopathy of Prematurity. "Retinapatia del Prematuro V" -June 10-11, 2005. Universidad Autonoma de San Luis Potosi, Cuidad San Luis Potosi, SLP.
Internatinal Symposium of Retinopathy of Prematurity. "Enfermedad Preumbral y Umbral", June 10-11, 2005. Universidad Autonoma de San Luis Potosi, Cuidad San Luis Potosi, SLP.
Advances in the Treatment of Neovascular AMD with Macugen- May 19, 2005, Beverly Hills, California Pfizer Ophthalmics.
Advances in the Treatment of Neovascular AMD with Macugen- May 19, 2005, Meeting in Medicine Teleconference.
Advances in the Treatment of Neovascular AMD with Macugen- May 18 2005, Pasadena, California Pfizer Opthalmics.
Texas Update on the Management of Diabetic Retinopathy and It's Complications-April 16, 2005, Houston, Texas.
Inhibidores de Factor de Crecimeiinto Vascular Endotelial en las Degeneracion Macular Relacionada con la Edad- March 18, 2005, Santiago, Chile XXV Pan-American Ccongress of Ophthalmology XXV Congreso Panaericano de Oftalmologia.
American Academy of Ophthalmology "Presente y Futuro de la Endoscopia Laser Ocular"- October 23, 2004. New Orleans, LA. Spanish.
Mexican Ccongress of Ophthalmology "Presente y Futuro de la Endoscopia Laser Ocular" -August 8, 2004. Veracruz, Mexico.
Nantucket Retina "Intravitreal Kenalog and the Risk of Severe Intraocular Pressure Rise" -July 29, 2004. Nantucket, MA.
Legends of Legacies "Perfluorhexyloctane in the Management of Complicated Retinal Detachment" -May 14, 2004. Ausitn, TX.
The Art of Living with Low Vision "Advances in Macular Degeneration" 'February 27, 2004, Mcallen, TX.
Annual Symposium of Diseases and Surgery of the Retina. Instituto Tecnologico y de Estudios Superiores de Monterrey. Monterrey, Nuevo Leon, Mexico.- May 30-31, 2003 "Medical treatment of Diabetic Retinopathy", "Triamcinolone use with Diabetic Macular Edema", "Cystoid Macular Edema Associated With the Pseudophakic Eye", "Argon Laser Photocoagulation in Age-Related Macular Sheathotomy" Spanish.
Texas Ophthalmological Association "Genetics of Diabetic Retinopathy" -April 5, 2003 San Antonio, TX.
Diabetes Discussion Group for the Lower Rio Grande Valley. Held by The Texas Medical Foundation- November 5, 2002. Harlingen, TX. "Update on Texa Diabetes Council's presents activities".
Region One School Nurse Institute- July 30, 2002. Mission, TX. "Diabetic Retinopathy".

Migrant Health Promotion and Texas Commission for the Blind. Progreso, TX-March 2002 “How Diabetes complications affect our eyes”

Tip O’Texas RV Resort Annual Health Fair. McAllen, TX- February 2002, 2003. “Diabetic Retinopathy”

Texas Commission for the Blind “Diabetic Retinopathy” -October 18, 2001 Austin, TX

2001 Border Academy- July 2001. “Ophthalmological Issues Surrounding Strategies in the Diagnosis and Treatment of the Mexican-origin Diabetic Patient” McAllen, TX

“Indocyanine Green in the Management of Macular Holes”, Schepens International Society, Las Vegas, NV 2001

Texas Medical Association “Surgical Decompression of Branch Retinal Vein Occlusion” -May 26, 2000 Austin, TX

“Management of Choroidal Neovascularization With Photodynamic Therapy Using Visudyne” Retinal Disease Conference, New Orleans, LA- April 8, 2000

Edinburg Chamber of Commerce Seminar on Macular Degeneration- March 3, 1999.  Edinburg, Texas.  “Macular Degeneration”

Diabetes Management Symposium: Strategies for Health Care Personnel.  South        Padre Island, TX. “Eye Care” -February 9, 1999

Valley Retinal Medical Center. Update on Diabetes-November 7, 1998
“Diabetic  Retinopathy.” Brownsville, Texas

“Diabetes and your Eyes”-September 1998, Health Capsules.

“Diabetic Retinopathy Screening and Indication for Treatment”, Dallas, TX- August 1998

Nantucket Retina Meeting, Nantucket, Massachusetts- July 1998 “Retina Angiomatosis”.

“Diabetic Retinopathy Screening and Treatment”, Reynosa, Mexico- May 1998

McAllen Medical Center, McAllen Texas-February 1998. “Macular Degeneration Conference,” The Aging Eye”

Good Neighbor Pharmacy Seminar. McAllen, TX-May 18, 1997

Roche Laboratories, McAllen, TX -April 30, 1997, “Update on CMV: Diagnosis and Management”

McAllen Medical Center & Edinburg Regional Medical Center, McAllen, TX-March 11, 1997  “For Fitness Sake: Care For Aging Eyes”

Diabetes Support Group Meeting, McAllen, TX-February 6, 1997 “Taking Care of your eyes”.

Monterrey Ophthalmological Society, Monterrey, NL Mexico-February 1997, “Retinopathy of Prematurity Update”

South Texas Organ Bank, South Padre Island Texas- April 1995-1998. “Angels are Among Us - Organ Bank Symposium”

Advances in Diagnostic Imaging, Massachusetts Eye and Ear Infirmary, Boston, MA, January 1993.   “Color Doppler Ultrasound in the Evaluation of Choroidal Melanoma Treatment Response to Photodynamic Therapy”

Residents’ Day, Doheny Eye Institute, Los Angeles, CA, June 1992. “A Pigmented Choroidal Melanoma Model in the Rabbit”

All Day Clinical Conference, Doheny Eye Institute, Los Angeles, CA, December 1991. “Advances in the Management of Giant Retinal Tears”

Residents’ Day, Doheny Eye Institute, Los Angeles, CA, June 1991. “Ocular Findings in Extracorporeal Membrane Oxygenator Survivors”

All Day Clinical Conference, Doheny Eye Institute, Los Angeles, CA, December 1990. “Controversies in the Diagnosis of Choroidal Melanomas”

Residents’ Day, Doheny Eye Institute, Los Angeles, CA, June 1990. “Family Studies of Keratoconus”

All Day Clinical Conference, Doheny Eye Institute, Los Angeles, CA, December 1989. “Current Approach and Treatment of Vernal Conjunctivitis”

37th Annual Conference of the National Council on the Aging, Chicago, IL. April 1987. “The Effect of Aging on T-cell Activation via the CD2 Receptor”

 

 

Clinical Research

Principal Investigator: Diabetic Retinopathy Clinical Research Network. Treatment for Central Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity. -2014-Active.

Principal Investigator: A multi-center study of the efficacy and safety of the human  anti_TNF monocolonal antibody adalimumab as maintenance therapy in subjects’ with intermediate-, posterior-, or pan-uveitis.  (M10-877).2013-Active.

Principal Investigator: A multi-center open-label study of the long-term safety and efficacy of the human anti-TNF monoclonal antibody adalimumab in subjects with noninfectious intermediate-, posterior-, or pan-uveitis. (M11-327). 2013-Active.

Principal Investigator: Diabetic Retinopathy Clinical Research Network. Genes in Diabetic Retinopathy Project.(Genes study). 2013-Active.

Prinicipal Investigator: A randomized, double-masked, placebo-controlled study of the Safety and efficacy of Gevokizumab in the treatment of Active non-infections intermediate, posterior, or Pan-uveitis. (XOMA). 2013-Active.

Prinicipal Investigator: A randomized, placebo controlled, parallel, double-masked study to evaluate the efficacy and safety of two doses of oral optina in adult patients with diabetic macular edema. (Optina) . 2013-Active.

Principal Investigator: Ozurdex vs Ranibizumab vs combination for Central Retinal Vein Occlusion (ORION). 2013-Active.

Principal Investigator: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety   and Efficacy of Intravitreous Administration of Fovista(TM) (ANTI PDGF-B  PEGYLATED   APTAMER) Adminstered  in Combination  with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration (OPH1003). 2013-Active.

Principal Investigator: Diabetic Retinopathy Clinical Research Network. A Phase II Evaluation of Topical NSAIDs in Eyes with Non Central Involved DME. (Protocol R). 2012-Closed.

Principal Investigator: Diabetic Retinopathy Clinical Research Network. Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.( Protocol S). 2012-Active

Principal Investigator: Diabetic Retinopathy Clinical Research Network. A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema. (Protocol T). 2012-Active.

Principal Investigator: A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI] in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. Protocol# VGFTe-RVO-1027. 2012-Active.

Principal Investigator:  Diabetic Retinopathy Clinical Research Network. Effect of Diabetes Education during Retinal Ophthalmology Visits on Diabetes Control (Protocol M). 2012-Active.

Principal investigator: A Phase 2 Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Multi-Dose Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of rn6g (PF-04382923) in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration. Study # B1181003 – 1060. 2012-Closed.

Principal Investigator: An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety of PF-04523655 Alone and in Combination with Ranibizumab Versus Ranibizumab Alone in Diabetic Macular Edema (MATISSE  STUDY). 2012-Closed.

Principal Investigator: A Randomized, Sham-Controlled, Double-Masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (TG-MV-014 Oasis). 2011-Closed.

Principal Investigator: An Open-Label , Multi-center Extension Study Of The Safety And Utility Of The New Inserter of ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg and The Safety of ILUVIEN in Subjects With  Diabetic Macular Edema. 2011-Closed.

Principal Investigator: A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel)-Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects with Choroidal Neovascularization (CNV) Associated with Age-Related Macular Degeneration (AMD). CLIN905  MLT202. 2011-Closed.

Principal Investigator: A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Protocol # VGFT-OD-1009.01. 2011-Active.

Principal Investigator: A Phase 2A, Multi-Center, Blinded, Randomized, Comparator-Controlled Study Evaluating ISONEP (Sonepcizuman[LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin alone in the treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Protocol# LT1009-Oph-003. 2011-Active.

Principal investigator: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as             Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the       Treatment of Diabetic Macular Edema with Involvement of the Foveal Center             (iDEAL Study). 2011-Active.

Sub- investigator: Safety and efficacy of difluprednate 0.05% for the treatment  of anterior uveitis.
C-10-034. 2011-Closed.

Principal Investigator: A Phase IV, Open Label, Multi-center Study to Assess the Effect of intravitreal Injections of Macugen (Pegaptanib Sodium Injection)          Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium. Protocol: EOP-1024. 2011-Active.

Principal investiagator: A Phase 1 / 2 Trial to Investigate the Safety and Tolerability of Single and Repeated Doses of Hi-Con1™ Following Administration by Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration (amd). Protocol It-001A. 2011- Closed.

Principal Investigator:  Diabetic Retinopathy Clinical Research Network. An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (Protocol N) 2010-Closed.

Principal Investigator: Controlled, double-masked, randomized, multicenter study to evaluate AL-78898A, 5.25mg as a treatment for exudative AMD. (RACE). 2010-Closed.

Principal Investigator: A randomized, sham-controlled, double masked, multicenter     trial of Ocriplasmin Intravitreal Injection  For Treatment of Focal Vitreomacular Adhesion in Subjects with Exudative Age Related Macular Degeneration (AMD) TG-MV-005 . 2010-Closed.

Principal Investigator: A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients Protocol No. C-09-003 (Alcon MIZAR Study) 2010-Closed.

Principal Investigator: A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients.
 Protocol#: C-07-43 2009-Closed.

Principal Investigator:  A Double-Masked, Randomized, Controlled of the Study, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME). REGENERON Pharmaceuticals, Inc. Protocol VGFT-OD-0706 2009-Closed.

Principal Investigator: A Phase I, Open-Label, Dose Escalation Clinical Study to Assess the Safety and tolerability of NOVA63035 in Patients with Diabetic Macula Edema Secondary to Diabetic Retinopathy. RETIJECT PROTOCOL NVG07D108 2009-Closed.

Principal Investigator:  Diabetic Retinopathy Clinical Research Network. A Pilot Study in Individuals with Center-Involved DME Undergoing Cataract Surgery (Protocol P) 2009-Closed.

Principal Investigator:  Diabetic Retinopathy Clinical Research Network. An Observational Study in Individuals with Diabetic Retinopathy without Center-Involved DME Undergoing Cataract Surgery (Protocol Q) 2009-Closed.

Principal Investigator: Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (Preserve) Study. 2009-Closed.

Principal Investigator:  Macugen for Proliferative Diabetic Retinopathy Study: With extended Dosing (M-PDRS ED): A pilot study to determine if intravitreal injections of Pegaptanib Sodium (Macugen) given every 12 weeks for a year after an induction phase of three injections every 6 weeks will reduce the progression of proliferative diabetic retinopathy in patients without significant vitreous hemorrhage in comparison to treatment with retinal photocoagulation alone and after an induction phase. Protocol#: M-PDRS ED. 2009-Closed.

Principal Investigator: Diabetic Retinopathy Clinical Research Network. Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema.(Protocol O) . 2009-Closed.

Principal Investigator: A phase III , double masked , multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 0.2 mg Ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration( FVF4579g). 2009-Closed.

Principal Investigator: A randomized, Double-masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. (Protocol VGFT-OD-0605) 2007-Closed.

Principal Investigator: A phase III, double masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety or ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes  mellitus( FVF4170g RISE) . 2007-Closed.

Principal Investigator:  A Phase 3 B, Multicenter Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Protocol FVF3689g. 2006-Closed.

Principal Investigator: A Phase II, Randomized, Dose –Ranging, Double – Masked, Multicenter Trial, in Parallel Groups, to Determine the Safety, Efficacy and Pharmokinetics of Intravitreous Intravitreal Injections of Pegaptanib Sodium Compared to Sham Injections for  30 Weeks in Patients with Recent Vision Lost due to Macular Edema Secondary to CRVO. Protocol EOP1011D. 2005-Closed.

Principal Investigator: A Phase 3 B, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, In Parallel Groups, To Compare The Safety and Efficacy of Intravitreous Injections of Macugen Given Every 6 Weeks For 54 Weeks (To Be Extended To 102 Weeks As Indicated) Plus Sham Photodynamic Therapy (PDT), To Macugen Plus PDT With Visudyne, In Subjects With Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Protocol EOP1012C. 2005-Closed.

Principal Investigator:  An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-sponsored Ranibizumab Study. Protocol FVF3426g. 2005-Closed.

Principal Investigator: A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel of Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pegaptanib Sodium (Macugen), Given as often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula. Protocol EOP1013B. 2005-Closed.

Principal Investigator: Macugen® for Proliferative Diabetic Retinopathy Study (M-PDRS): A Pilot Study to determine if Intravitreal Injections of Macugen® (pegaptanib sodium) will reduce the Progression of Proliferative Diabetic Retinopathy in Patients without Significant Vitreous Hemorrhage. FDA IND #73,308. 2005-Closed.

Principal Investigator: An Open-Label Assessment of Intravitreous Injections of Vitrase® (Hyaluronidase for Injection) for Inducing Posterior Vitreous Detachment in Subjects with Moderate to Severe Non-Proliferative Diabetic Retinopathy. Protocol Number ISTA-VIT-CS07. 2005-Closed.

Principal Investigator:  A Phase II Prospective, Randomized, Double-Masked, Sham Controlled, Dose Ranging, Multicenter Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-Related Macular Degeneration. Protocol EOP1009. 2004-Closed.

Principal Investigator: An Open Label, Non-Comparative Protocol For the Use of Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration. Protocol EOP1010. 2004-Closed.

Principal Investigator: A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema. Diabetic Retinopathy Clinical Research Network, Protocol B. 2004-Closed.

Principal Investigator:  A Temporal Variation in Optical Coherence Tomography Measurements of Retinal Thickening in Diabetic Macular Edema. Diabetic Retinopathy Clinical Research Network, Protocol C. 2004-Closed.

Principal Investigator:  A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema. Diabetic Retinopathy Clinical Research Network, Protocol E. 2004-Closed.

Sub-Investigator: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion. 2004-Closed.

Principal Investigator:  A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration. Protocol FVF2598g. 2003-Closed.

Principal Investigator:  A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared with Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration. Protocol FVF2587g. 2003-Closed.

Principal Investigator:  A Phase II Randomized, Multicenter, Dose-Ranging, Controlled, Parallel-Group Trial to Assess the Safety and Efficacy of Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in the Treatment of Persistent Macular Edema. Protocol DC103-06-02. 2001-Closed.

Principal Investigator:  An Open-Label, Multicenter, Safety Study of the Treatment of Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) using Photodynamic Therapy with Verteporfin for Injection. Protocol BPD OCR 005. 2000-Closed.

Co-Investigator: Genetics of Diabetic Retinopathy, Department of Public Health, University of Houston, Texas. National Eye Institute R01 Grant FY 12386-01. 2000–Closed.

Principal Investigator: Phase III Safety and Efficacy Study of Vitrase (Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage. Protocol VIT-02-08961X. Dated 24 August1998. Revision #2: 1998-Closed.

 

 

Phone: (956) 631-8875
FAX: (956) 631-9134
www.valleyretinainstitute.com

research : services : insurance : forms : organizations